Fierce Biotech August 29, 2024
Nick Paul Taylor

Johnson & Johnson has taken another step toward realizing a return on its $6.5 billion nipocalimab bet, filing for FDA approval to challenge argenx and UCB for the generalized myasthenia gravis (gMG) market.

J&J acquired the FcRn blocker in its takeover of Momenta Pharmaceuticals in 2020. The drugmaker sees nipocalimab as a candidate that can generate peak sales in excess of $5 billion, despite argenx and UCB beating it to market. Argenx won approval for Vyvgart in 2021. UCB secured authorization for Rystiggo in 2023. All the companies are working to establish their products in multiple indications.

With J&J disclosing its first filing for FDA approval of nipocalimab on Thursday, the Big Pharma is set to cede a multi-year...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article